[1]魏倩 梁岩.新型口服抗凝药物与维生素K拮抗剂相关的脑出血风险对比[J].心血管病学进展,2020,(5):441-443.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.001]
　WEI Qian,LIANG Yan.Comparison of Risk of Related Intracerebral Hemorrhage Between Non-vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists[J].Advances in Cardiovascular Diseases,2020,(5):441-443.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.001]
点击复制

新型口服抗凝药物与维生素K拮抗剂相关的脑出血风险对比()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年5期
页码:
441-443
栏目:
出版日期:
2020-05-25

文章信息/Info

Title:
Comparison of Risk of Related Intracerebral Hemorrhage Between Non-vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists
作者:
魏倩 梁岩
中国医学科学院 北京协和医学院阜外医院急重症中心,北京 100037)
Author(s):
WEI Qian; LIANG Yan
(Emergency Center,Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College,Beijing 100037,China)
关键词:
抗凝药物; 华法林; 脑出血
Keywords:
Anticoagulants; Warfarin; Intracerebral hemorrhage
DOI:
10.16806/j.cnki.issn.1004-3934.2020.05.001
摘要:
新型口服抗凝药物是血栓预防和治疗的一个重要组成部分，它能有效地用于非瓣膜性心房颤动患者的卒中预防、深静脉血栓的预防与治疗等，但其仍有引起出血并发症的风险。目前的研究表明，新型口服抗凝药物相关的脑出血风险与维生素K拮抗剂相比无显著差异甚至更低；新型口服抗凝药物治疗心房颤动合并脑出血的患者时，缺血性卒中和复发性脑出血的风险与华法林相比无显著降低；新型口服抗凝药物相关的脑出血的血肿特征和功能预后与维生素K拮抗剂相比无显著差异，甚至血肿体积更小，预后更好。
Abstract:
Non-vitamin K antagonist oral anticoagulants(NOACs) are an important part of thromboembolism prevention and treatment. They can effectively prevent stroke in patients with nonvalvular atrial fibrillation and prevent and treat deep vein thrombosis, but they still have the risk of bleeding. Current studies have shown that the risk of NOACs related intracerebral hemorrhage was not significantly different or lower than that of vitamin K antagonist related intracerebral hemorrhage.Compared with warfarin, the risk of ischemic stroke and recurrent cerebral hemorrhage in patients with atrial fibrillation and cerebral hemorrhage treated with NOACs was not significantly reduced.Compared with vitamin K antagonists, the hematoma characteristics and functional prognosis of NOACs related intracerebral hemorrhage have no significant difference, even the hematoma volume is smaller and the prognosis is better.

参考文献/References:

[1] 闻雪松,张冬颖. 新型口服抗凝药不良反应研究进展[J].心血管病学进展,2019,40(3): 429-432.

[2] Katsanos AH,Schellinger PD,K?hrmann M,et al. Fatal oral anticoagulant-related intracranial hemorrhage:a systematic review and meta-analysis[J]. Eur J Neurol,2018,25(10):1299-1302.

[3] Green L,Tan J,Morris JK,et al. A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study)[J]. Haematologica,2018,103(4):738-745.

[4] Soo Y,Abrigo J,Leung KT,et al. Correlation of non-vitamin K antagonist oral anticoagulant exposure and cerebral microbleeds in Chinese patients with atrial fibrillation[J]. J Neurol Neurosurg Psychiatry,2018,89(7):680-686.

[5] Nielsen PB,Skj?th F,S?gaard M,et al. Non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with intracerebral hemorrhage[J]. Stroke,2019,50(4):939-946.

[6] Badi MK,Vilanilam GK,Gupta V,et al.Pharmacotherapy for patients with atrial fibrillation and cerebral microbleeds[J].J Stroke Cerebrovasc Dis,2019,28(8):2159-2167.

[7] Chen SJ,Yeh SJ,Tang SC,et al. Similar outcomes between vitamin K and non-vitamin K antagonist oral anticoagulants associated intracerebral hemorrhage[J]. J Formos Med Assoc,2020,119(1):106-112.

[8] Gerner ST,Kuramatsu JB,Sembill JA,et al. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage[J].Ann Neurol,2018,83(1):186-196.

[9] Woo HG,Chung I,Gwak DS, et al. Intracerebral hemorrhage associated with warfarin versus non-vitamin K antagonist oral anticoagulants in Asian patients[J].J Clin Neurosci,2019,61:160-165.

[10] Tsivgoulis G,Wilson D,Katsanos AH,et al. Neuroimaging and clinical outcomes of oral anticoagulant-associated intracerebral hemorrhage[J]. Ann Neurol,2018,84(5):694-704.

[11] Lioutas VA,Goyal N,Katsanos AH,et al. Clinical outcomes and neuroimaging profiles in nondisabled patients with anticoagulant-related intracerebral hemorrhage[J]. Stroke,2018,49(10):2309-2316.

相似文献/References:

[1]王鹏举,综述,陈茂,等.华法林相关性肾病[J].心血管病学进展,2016,(2):167.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.018]
　WANG Pengju,CHEN Mao.Warfarin-related Ephropathy[J].Advances in Cardiovascular Diseases,2016,(5):167.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.018]
[2]徐风燕 孙飞龙.非瓣膜性心房颤动患者华法林抗凝质量的临床研究[J].心血管病学进展,2020,(8):868.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.021]
　XU Fengyan,SUN Longfei.(Department of Cardiology,Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University,Urumqi 831100,Xinjiang,China)[J].Advances in Cardiovascular Diseases,2020,(5):868.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.021]
[3]曾谷雨 袁晋青.慢性冠状动脉综合征二级预防的抗血小板及抗凝治疗研究进展[J].心血管病学进展,2021,(12):1061.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.002]
　ZENG Guyu,YUAN Jingqing.Antiplatelet and Antithrombotic Therapy for the Secondary Prevention of Chronic Coronary Syndrome[J].Advances in Cardiovascular Diseases,2021,(5):1061.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.002]
[4]向珍贤 罗素新 黄毕.瓣膜性房颤和非瓣膜性房颤的区别和抗凝策略的差异[J].心血管病学进展,2023,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.010]
　XIANG ZhenxianLUO SuxinHUANG Bi.The Difference of Definition and Anticoagulation Therapy Strategies Between Valve and Non-valve Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2023,(5):142.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.010]
[5]多力昆·木台力甫?阿布都赛米·艾尼 阿布都乃比·麦麦提艾力.青年女性患者心脏瓣膜的选择[J].心血管病学进展,2024,(6):489.[doi:10.16806/j.cnki.issn.1004-3934.202.06.003]
　Duolikun·Mutailifu,Abudusaimi·Aini,Abudunaibi·Maimaitiaili.Duolikun·Mutailifu1,Abudusaimi·Aini1,Abudunaibi·Maimaitiaili2[J].Advances in Cardiovascular Diseases,2024,(5):489.[doi:10.16806/j.cnki.issn.1004-3934.202.06.003]

更新日期/Last Update: 2020-08-11